InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,634.54
(
0.69%
)
US TECH 100
19,054.29
(
0.66%
)
Dow Jones
41,458.41
(
0.88%
)
Brent Oil
71.39
(
-0.81%
)
Bitcoin
59,730.44
(
2.74%
)
Post# of 253114
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120427
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: Preciouslife1 post# 68940

Monday, 11/24/2008 4:14:45 PM

Monday, November 24, 2008 4:14:45 PM

Post# of 253114
The ALO buyout is odd in that KG now has commercial rights to two very similar drugs: Remoxy from PTIE and Embeda from ALO. Both drugs went before the same FDA advisory panel last week (#msg-33561355, #msg-33590952).

I have to assume that KG thinks there’s a fairly high chance that Emebda will get FDA approval and Remoxy won’t; otherwise, I fail to see the impetus for the buyout.

Comments welcome.


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up